PUBLISHER: Market Xcel - Markets and Data | PRODUCT CODE: 1509675
PUBLISHER: Market Xcel - Markets and Data | PRODUCT CODE: 1509675
Pharmaceutical Contract Manufacturing Market Assessment, By Service, By Dosage Form, By End-user, By Region, Opportunities and Forecast, 2017-2031F
Global pharmaceutical contract manufacturing market is projected to witness a CAGR of 7.07% during the forecast period 2024-2031F, growing from USD 207.06 billion in 2023 to USD 357.63 billion in 2031F. The rapid expansion of the pharmaceutical sector, increasing investments in generics, technological advancements, and successful mergers and acquisitions are some of the major drivers that are expected to aid the growth of the market.
The expansion of the market in various regions across the globe is supported by the rise in the cases of chronic diseases and disorders and infectious diseases as they propel the requirement for pharmaceutical products. According to estimates from the World Health Organization (WHO), cardiovascular diseases are one of the leading causes of death, killing approximately 17.9 million individuals every year. The augmentation of such chronic diseases will bolster the requirement for various therapeutic solutions in order to effectively treat and manage the conditions, thus providing lucrative growth opportunities to the market. This is because the drug production process requires specialized facilities and equipment, and the process of setting up a pharmaceutical production facility can often be time-consuming and economically draining. Therefore, various companies rely on pharmaceutical contract manufacturing companies to meet the growing demand for therapeutic drugs.
The growth of the market is also supported by the wide range of benefits offered by pharmaceutical contract manufacturers, including reduced time, cost efficiency, increased flexibility, and compliance benefits. Meanwhile, the increasing partnerships and acquisitions are also supporting the expansion of the market. In June 2024, Great Point Partners, LLC acquired Lyocontract GmbH. The acquisition will aid the latter in broadening their product offerings and expanding their global footprint. The capital resources of Great Point combined with the contract manufacturing capabilities of Lyocontract will allow both companies to deliver high-quality products.
Expansion of the Pharmaceutical Sector Boosts Market Demand
The rapid expansion of the pharmaceutical sector in the coming years is expected to bolster the global pharmaceutical contract manufacturing market growth. The European Federation of Pharmaceutical Industries and Association estimates that North America accounted for 53.3% of global pharmaceutical sales in 2023, and Europe accounted for 22.7% of the sales. This increase is expected to aid the expansion of the market as pharmaceutical contract manufacturing aids the optimization of operational expenses. Due to the rising demand for pharmaceutical products, various companies rely on contract manufacturing companies as they provide an agile approach for testing, assembling secondary packaging, manufacturing, and primary packaging. Thus, providing lucrative growth opportunities to the market in the coming years.
Additionally, the increasing expiration of blockbuster drugs and biologics is also expected to aid the expansion of the market. Due to this expiration, the demand for generics of blockbuster drugs is anticipated to rise, which in turn is expected to propel the demand for pharmaceutical contract manufacturing to meet this rising demand. This is because pharmaceutical companies are focused on developing novel therapeutic solutions and prefer outsourcing drug manufacturing to contract manufacturing organizations. Meanwhile, the growing threat of chronic diseases in different regions across the globe is also providing lucrative growth opportunities to the market. The increasing cases of chronic diseases are anticipated to bolster the requirement for various therapeutic solutions, which in turn is expected to augment the requirement for pharmaceutical contract manufacturing.
Increasing Prevalence of Chronic Diseases Supports Market Expansion
The rising requirement for effective therapies for treating various chronic diseases can be attributed to the growing burden of diseases in various regions across the globe. The American Cancer Society estimates that 2,001,140 new cases and 611,720 deaths related to cancer are expected to occur in 2024 in the United States. This increase in the number of cancer cases will augment the demand for oncology drugs, boosting the growth of the market. Furthermore, rising collaborations between various regulatory entities, research institutions, and pharmaceutical companies to expedite the drug development processes and foster innovation while ensuring the safety of the patients are also expected to offer lucrative growth opportunities to the market. Additionally, various companies are also investing in contract development and manufacturing facilities to address the rising demand for cancer therapies. In June 2022, Merck KGaA announced the opening of their new 70,000 square feet facility in Wisconsin, United States, to double the production capacity of their high-potency active pharmaceutical ingredients to meet the growing requirement of cancer therapies.
North America Expected to Account for Significant Market Share
The growth of the market in North America is supported by the rising requirement for generics, the expansion of the aging population, increasing cases of chronic diseases, and the strong presence of key market players in the region. The increasing prevalence of various chronic diseases and disorders, such as diabetes and cancer, in the region is bolstering the requirement for effective drugs for treating these conditions. According to estimates from the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 29.7 million individuals of all ages, roughly 8.9% of the population, have been diagnosed with diabetes. The increasing cases of such conditions are propelling the requirement for effective drugs for their management and treatment, which, in turn, is augmenting the market demand.
Generic Pharmaceutical Companies are Expected to Witness Growth
The generic pharmaceutical companies are expected to witness significant growth in the coming years. This growth of the segment can be attributed to the expiration of branded drugs and the increasing requirement for generic drugs. The increasing requirement for generics can be attributed to the growing awareness of their potential to enhance healthcare accessibility by offering economically efficient alternatives to expensive biological therapies. According to estimates from the Association for Accessible Medicines (AAM), biosimilar and generic prescriptions account for 90% of the total prescriptions filled in the United States. Furthermore, the biosimilar and generic drugs generated USD 408 billion for the American healthcare system and its patients in 2022. This growth of biosimilar and generic drugs, is in turn, positively influencing the expansion of the market. Additionally, the rising prevalence of several genetic disorders, chronic diseases, and infectious diseases in various regions across the globe are propelling the requirement for safe and effective medications, thus bolstering the demand for pharmaceutical contract manufacturing as they aid in providing quality-assured products in a cost-efficient manner.
Future Market Scenario (2024-2031F)
According to the global pharmaceutical contract manufacturing market analysis, contract manufacturing is expected to play a significant role in the pharmaceutical industry in the coming years, and the integration of novel technologies, such as machine learning and artificial intelligence, is anticipated to aid in enhancing the operations of pharmaceutical contract manufacturing. The deployment of real-time monitoring solutions due to the advent of the Internet of Things (IoT) for ensuring that the quality is maintained during the production process and response is generated for any issues in a time-efficient manner is expected to enhance the reliability and efficiency of the supply chain in pharmaceutical contract manufacturing.
Key Players Landscape and Outlook
Successful mergers and acquisitions are expected to boost the global pharmaceutical contract manufacturing market size. In February 2024, Novo Holdings A/S and Catalent, Inc. announced that they have entered into a merger agreement, and Novo Holdings will be acquiring Catalent for USD 16.5 billion. Novo Holdings will be transferring Catalent's manufacturing sites to Novo Nordisk A/S to boost their efforts to meet the growing demand for their injectable obesity and semaglutide-based diabetes drugs Wegovy and Ozempic. The acquired sites are expected to aid the company's filling capacity from 2026. This investment is expected to aid Novo Nordisk in enhancing its key product offerings and providing premium manufacturing and development solutions to biotech and pharma customers.
The increase in investments by the key market players in drug production facilities is also expected to bolster the growth of the market. In May 2023, Thermo Fisher Scientific Inc. opened a drug production facility in Singapore. The facility is expected to support the company's general manufacturing and development services and the Singapore Economic Development Board (EDB). The sterile fill-finish facility contains an automated aseptic fill-finish line with advanced isolator technology for small and large-sized molecules and vaccines.
Table of Contents
1. Research Methodology
2. Project Scope & Definitions
3. Executive Summary
4. Global Pharmaceutical Contract Manufacturing Market Outlook, 2017-2031F
- 4.1. Market Size & Forecast
- 4.1.1. By Value
- 4.2. By Service
- 4.2.1. Pharmaceutical Manufacturing Services
- 4.2.1.1. Pharmaceutical FDF Manufacturing Services
- 4.2.1.2. Pharmaceutical API Manufacturing Services
- 4.2.2. Biologic Manufacturing Services
- 4.2.2.1. Biologic FDF Manufacturing Services
- 4.2.2.2. Biologic API Manufacturing Services
- 4.2.3. Drug Development Services
- 4.2.1. Pharmaceutical Manufacturing Services
- 4.3. By Dosage Form
- 4.3.1. Oral Solids
- 4.3.2. Oral Liquid
- 4.3.3. Emulsions
- 4.3.4. Parenteral
- 4.3.5. Others
- 4.4. By End-user
- 4.4.1. Big Pharmaceutical Companies
- 4.4.2. Small and Mid-Sized Pharmaceutical Companies
- 4.4.3. Generic Pharmaceutical Companies
- 4.4.4. Others
- 4.5. By Region
- 4.5.1. North America
- 4.5.2. South America
- 4.5.3. Europe
- 4.5.4. Asia-Pacific
- 4.5.5. Middle East & Africa
- 4.6. By Company Market Share (%), 2023
5. Global Pharmaceutical Contract Manufacturing Market Outlook, By Region, 2017-2031F
- 5.1. North America*
- 5.1.1. Market Size & Forecast
- 5.1.1.1. By Value
- 5.1.2. By Service
- 5.1.2.1. Pharmaceutical Manufacturing Services
- 5.1.2.1.1. Pharmaceutical FDF Manufacturing Services
- 5.1.2.1.2. Pharmaceutical API Manufacturing Services
- 5.1.2.2. Biologic Manufacturing Services
- 5.1.2.2.1. Biologic FDF Manufacturing Services
- 5.1.2.2.2. Biologic API Manufacturing Services
- 5.1.2.3. Drug Development Services
- 5.1.2.1. Pharmaceutical Manufacturing Services
- 5.1.3. By Dosage Form
- 5.1.3.1. Oral Solids
- 5.1.3.2. Oral Liquid
- 5.1.3.3. Emulsions
- 5.1.3.4. Parenteral
- 5.1.3.5. Others
- 5.1.4. By End-user
- 5.1.4.1. Big Pharmaceutical Companies
- 5.1.4.2. Small and Mid-Sized Pharmaceutical Companies
- 5.1.4.3. Generic Pharmaceutical Companies
- 5.1.4.4. Others
- 5.1.5. United States*
- 5.1.5.1. Market Size & Forecast
- 5.1.5.1.1. By Value
- 5.1.5.2. By Service
- 5.1.5.2.1. Pharmaceutical Manufacturing Services
- 5.1.5.2.1.1. Pharmaceutical FDF Manufacturing Services
- 5.1.5.2.1.2. Pharmaceutical API Manufacturing Services
- 5.1.5.2.2. Biologic Manufacturing Services
- 5.1.5.2.2.1. Biologic FDF Manufacturing Services
- 5.1.5.2.2.2. Biologic API Manufacturing Services
- 5.1.5.2.3. Drug Development Services
- 5.1.5.2.1. Pharmaceutical Manufacturing Services
- 5.1.5.3. By Dosage Form
- 5.1.5.3.1. Oral Solids
- 5.1.5.3.2. Oral Liquid
- 5.1.5.3.3. Emulsions
- 5.1.5.3.4. Parenteral
- 5.1.5.3.5. Others
- 5.1.5.4. By End-user
- 5.1.5.4.1. Big Pharmaceutical Companies
- 5.1.5.4.2. Small and Mid-Sized Pharmaceutical Companies
- 5.1.5.4.3. Generic Pharmaceutical Companies
- 5.1.5.4.4. Others
- 5.1.5.1. Market Size & Forecast
- 5.1.6. Canada
- 5.1.7. Mexico
- 5.1.1. Market Size & Forecast
All segments will be provided for all regions and countries covered
- 5.2. Europe
- 5.2.1. Germany
- 5.2.2. France
- 5.2.3. Italy
- 5.2.4. United Kingdom
- 5.2.5. Russia
- 5.2.6. Netherlands
- 5.2.7. Spain
- 5.2.8. Turkey
- 5.2.9. Poland
- 5.3. Asia-Pacific
- 5.3.1. India
- 5.3.2. China
- 5.3.3. Japan
- 5.3.4. Australia
- 5.3.5. Vietnam
- 5.3.6. South Korea
- 5.3.7. Indonesia
- 5.3.8. Philippines
- 5.4. South America
- 5.4.1. Brazil
- 5.4.2. Argentina
- 5.5. Middle East & Africa
- 5.5.1. Saudi Arabia
- 5.5.2. UAE
- 5.5.3. South Africa
6. Market Mapping, 2023
- 6.1. By Service
- 6.2. By Dosage Form
- 6.3. By End-user
- 6.4. By Region
7. Macro Environment and Industry Structure
- 7.1. Supply Demand Analysis
- 7.2. Import Export Analysis
- 7.3. Value Chain Analysis
- 7.4. PESTEL Analysis
- 7.4.1. Political Factors
- 7.4.2. Economic System
- 7.4.3. Social Implications
- 7.4.4. Technological Advancements
- 7.4.5. Environmental Impacts
- 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
- 7.5. Porter's Five Forces Analysis
- 7.5.1. Supplier Power
- 7.5.2. Buyer Power
- 7.5.3. Substitution Threat
- 7.5.4. Threat from New Entrant
- 7.5.5. Competitive Rivalry
8. Market Dynamics
- 8.1. Growth Drivers
- 8.2. Growth Inhibitors (Challenges and Restraints)
9. Regulatory Framework and Innovation
- 9.1. Patent Landscape
- 9.2. Regulatory Approvals
- 9.3. Innovations/Emerging Technologies
10. Key Players Landscape
- 10.1. Competition Matrix of Top Five Market Leaders
- 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
- 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
- 10.4. SWOT Analysis (For Five Market Players)
- 10.5. Patent Analysis (If Applicable)
11. Pricing Analysis
12. Case Studies
13. Key Players Outlook
- 13.1. Thermo Fisher Scientific Inc.
- 13.1.1. Company Details
- 13.1.2. Key Management Personnel
- 13.1.3. Products & Services
- 13.1.4. Financials (As reported)
- 13.1.5. Key Market Focus & Geographical Presence
- 13.1.6. Recent Developments
- 13.2. Abbvie Inc.
- 13.3. Lonza Group Ltd.
- 13.4. Boehringer Ingelheim International GmbH
- 13.5. Catalent, Inc.
- 13.6. Pfizer, Inc.
- 13.7. Evonik Industries AG
- 13.8. Dr. Reddy's Laboratories Ltd.
- 13.9. Jubilant Pharmova Limited
- 13.10. Recipharm AB
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work
14. Strategic Recommendations
15. About Us & Disclaimer
List of Tables
- Table 1. Pricing Analysis of Products from Key Players
- Table 2. Competition Matrix of Top 5 Market Leaders
- Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
- Table 4. About Us - Regions and Countries Where We Have Executed Client Projects
List of Figures
- Figure 1. Global Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 2. Global Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 3. Global Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 4. Global Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 5. Global Pharmaceutical Contract Manufacturing Market Share (%), By Region, 2017-2031F
- Figure 6. North America Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 7. North America Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 8. North America Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 9. North America Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 10. North America Pharmaceutical Contract Manufacturing Market Share (%), By Country, 2017-2031F
- Figure 11. United States Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 12. United States Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 13. United States Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 14. United States Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 15. Canada Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 16. Canada Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 17. Canada Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 18. Canada Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 19. Mexico Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 20. Mexico Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 21. Mexico Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 22. Mexico Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 23. Europe Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 24. Europe Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 25. Europe Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 26. Europe Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 27. Europe Pharmaceutical Contract Manufacturing Market Share (%), By Country, 2017-2031F
- Figure 28. Germany Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 29. Germany Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 30. Germany Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 31. Germany Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 32. France Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 33. France Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 34. France Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 35. France Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 36. Italy Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 37. Italy Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 38. Italy Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 39. Italy Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 40. United Kingdom Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 41. United Kingdom Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 42. United Kingdom Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 43. United Kingdom Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 44. Russia Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 45. Russia Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 46. Russia Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 47. Russia Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 48. Netherlands Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 49. Netherlands Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 50. Netherlands Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 51. Netherlands Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 52. Spain Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 53. Spain Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 54. Spain Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 55. Spain Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 56. Turkey Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 57. Turkey Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 58. Turkey Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 59. Turkey Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 60. Poland Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 61. Poland Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 62. Poland Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 63. Poland Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 64. South America Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 65. South America Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 66. South America Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 67. South America Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 68. South America Pharmaceutical Contract Manufacturing Market Share (%), By Country, 2017-2031F
- Figure 69. Brazil Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 70. Brazil Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 71. Brazil Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 72. Brazil Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 73. Argentina Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 74. Argentina Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 75. Argentina Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 76. Argentina Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 77. Asia-Pacific Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 78. Asia-Pacific Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 79. Asia-Pacific Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 80. Asia-Pacific Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 81. Asia-Pacific Pharmaceutical Contract Manufacturing Market Share (%), By Country, 2017-2031F
- Figure 82. India Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 83. India Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 84. India Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 85. India Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 86. China Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 87. China Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 88. China Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 89. China Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 90. Japan Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 91. Japan Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 92. Japan Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 93. Japan Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 94. Australia Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 95. Australia Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 96. Australia Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 97. Australia Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 98. Vietnam Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 99. Vietnam Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 100. Vietnam Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 101. Vietnam Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 102. South Korea Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 103. South Korea Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 104. South Korea Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 105. South Korea Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 106. Indonesia Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 107. Indonesia Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 108. Indonesia Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 109. Indonesia Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 110. Philippines Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 111. Philippines Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 112. Philippines Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 113. Philippines Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 114. Middle East & Africa Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 115. Middle East & Africa Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 116. Middle East & Africa Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 117. Middle East & Africa Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 118. Middle East & Africa Pharmaceutical Contract Manufacturing Market Share (%), By Country, 2017-2031F
- Figure 119. Saudi Arabia Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 120. Saudi Arabia Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 121. Saudi Arabia Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 122. Saudi Arabia Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 123. UAE Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 124. UAE Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 125. UAE Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 126. UAE Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 127. South Africa Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
- Figure 128. South Africa Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
- Figure 129. South Africa Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
- Figure 130. South Africa Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
- Figure 131. By Service Map-Market Size (USD Billion) & Growth Rate (%), 2023
- Figure 132. By Dosage Form Map-Market Size (USD Billion) & Growth Rate (%), 2023
- Figure 133. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
- Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
